In a significant move to bolster its immunology portfolio, GSK has announced the acquisition of RAPT Therapeutics for a staggering $22 billion. According to the official information, this deal, which was revealed on January 20, 2026, has sent shockwaves through the market, resulting in a dramatic increase in RAPT's stock price.
GSK's Acquisition of RAPT
The all-cash acquisition values RAPT at $58 per share, a substantial premium over its closing price of $35.10 just days prior on January 16. This strategic purchase underscores GSK's commitment to expanding its capabilities in the food allergy treatment sector, a growing area of interest in the pharmaceutical industry.
Market Reactions
Market reactions were overwhelmingly positive, with RAPT's stock soaring to approximately $57.52 during trading hours. The acquisition also sparked a surge in trading activity, with over 172 million shares changing hands, reflecting strong investor confidence in the future prospects of both companies.
On the same day as GSK's major acquisition announcement, ImmunityBio saw a significant rise in its stock price following positive FDA feedback regarding its drug ANKTIVA. For more details, click here.
